Numeta G19e (Valine, Ornithine Hydrochloride, Alanine, Arginine, Cysteine, Histidine, Isoleucine, Leucine, Methio)

The blend delivers a balanced profile of essential and conditionally essential amino acids directly into the bloodstream. Cells take up these amino acids and incorporate them into proteins, supporting anabolic processes, immune function and nitrogen balance while bypassing the gastrointestinal tract, which is crucial for patients with impaired digestion or absorption.

The dose of Numeta G19e is individualized by the prescribing clinician based on the patient’s weight, clinical condition, renal and hepatic function, and overall nutritional goals. Healthcare professionals calculate the appropriate infusion rate and total daily amount to meet the patient’s specific protein and caloric requirements.

Numeta G19e is generally reserved for patients with a clear medical indication for parenteral nutrition. Its safety in pregnancy or lactation has not been specifically established, so it should only be used if the potential benefit justifies any possible risk, and under close medical supervision.

To order Numeta G19e, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and required import documentation.

Numeta G19e offers a comprehensive amino‑acid profile designed for balanced protein synthesis, similar to other high‑quality parenteral nutrition solutions. Compared with older formulations that may lack certain essential amino acids, Numeta G19e provides a more physiologic composition, potentially improving nitrogen balance and reducing metabolic complications in critically ill patients.

Numeta G19e must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Before administration, allow the product to reach room temperature if required by the clinical protocol.

Numeta G19e is administered intravenously, typically via a peripheral or central venous catheter. The infusion rate is set by the healthcare provider based on the patient’s nutritional prescription, and the solution is usually diluted in compatible IV fluids according to institutional guidelines.

Serious risks include severe hypersensitivity reactions, metabolic acidosis, hyperammonemia in patients with liver dysfunction, and catheter‑related infections. Continuous monitoring of vital signs, laboratory parameters and infusion site is essential to detect and manage these complications promptly.

Numeta G19e should be avoided in patients with known hypersensitivity to any of its amino‑acid components, in those with uncontrolled metabolic disorders that could be worsened by amino‑acid infusion, and in individuals where a compatible IV solution is required to prevent precipitation. Clinical judgment is required for each case.